The Company’s headquarters is located at 24 West 40th Street, New York, NY 10018 and it maintains an office at 75/76 Wimpole Street London W1G 8LY UK.
 

Akari Therapeutics was formed in September 2015 through the merger of Volution Immuno Pharmaceuticals, SA into Celsus Therapeutics, Plc., which then changed its name to Akari Therapeutics, Plc.
 

Akari Therapeutics is a company organized under the laws of England and Wales. Its ordinary shares are not traded but it has American Depository Shares (ADS) (each of which represents 100 ordinary shares) listed on the NASDAQ Capital Market under the ticker symbol AKTX.
 

An ADS is a U.S. dollar-denominated equity share of a non-U.S. company available for purchase on an American stock exchange. ADSs are issued by depository banks in the U.S. under agreement with the issuing company.
 

This ratio reflects the number of ordinary shares that correspond to 1 ADS. In the case of Akari Therapeutics, each ADS represents 100 ordinary shares.
 

You can buy an ADS through a broker, just as you would any other U.S. securities.
 

If you hold ADSs in Akari Therapeutics please contact Akari Therapeutics’ depositary, Deutsche Bank. The office at which the ADSs are administered is located at 60 Wall Street, New York, NY 10005 or by telephone on (212) 250-2500. Please note, there may be a fee involved for replacing lost certificates.
 

For ADSs, you must send both your old and new addresses to Deutsche Bank, attention Beverly George, whose address is 60 Wall Street, New York, NY 10005.

Where shares are jointly held by more than one shareholder, each shareholder registered against the share in question must sign the request for an address change.
 

Akari Therapeutics’s fiscal year end is December 31st.
 

Akari Therapeutics’ independent auditor is BDO USA.
 

The Company’s transfer agent is AST.

You can contact AST via their website: www.astfinancial.com

Written requests by regular mail can be made to:
AST Financial
6201 15th Avenue
Brooklyn, New York 11219
 

The Company does not currently have a direct stock purchase plan.
 

The Company’s SEC filing can be accessed on the Financial Information page of the Investor Relations portion of its website or can be accessed directly from the SEC’s website at www.sec.gov.
 

You can submit questions to the Akari Therapeutics investor relations team by contacting ir@akaritx.co.